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Hepatitis C virus (HCV) enters human hepatocytes
through a multistep mechanism involving, among
other host proteins, the virus receptor CD81. How
CD81 governs HCV entry is poorly characterized,
and CD81 protein interactions after virus binding
remain elusive. We have developed a quantitative
proteomics protocol to identify HCV-triggered CD81
interactions and found 26 dynamic binding partners.
At least six of these proteins promote HCV infection,
as indicatedbyRNAi.We further characterized serum
response factor binding protein 1 (SRFBP1), which is
recruited to CD81 during HCV uptake and supports
HCV infection in hepatoma cells and primary human
hepatocytes. SRFBP1 facilitates host cell penetration
by all seven HCV genotypes, but not of vesicular sto-
matitis virus and human coronavirus. Thus, SRFBP1
is an HCV-specific, pan-genotypic host entry factor.
These results demonstrate the use of quantitative
proteomics to elucidate pathogen entry and under-
score the importance of host protein-protein interac-
tions during HCV invasion.
INTRODUCTION
Virus entry describes the process of delivering viral genomes in a
replication-competent manner into a naive host cell. Successful
penetration of cells involves receptor binding, virion uptake,
membrane fusion or perturbation, transport of nucleocapsids
to replication competent cellular compartments, and uncoating
(Yamauchi and Helenius, 2013). Virus receptors are more than
attachment factors, functionally supporting cell entry by several864 Cell Reports 12, 864–878, August 4, 2015 ª2015 The Authorsmeans: they mediate formation of receptor platforms, induce
conformational changes in virus surface molecules, transmit sig-
nals within the cell, and induce virus translocation along the
membrane and into the cell (Mercer et al., 2010). A number of
virus receptors, however, lack signaling domains. Consequently,
these receptors must initiate the virus uptake program through
ligand-dependent interaction with additional host proteins.
In this study, we focus on the entry mechanism of hepatitis C
virus (HCV), an enveloped RNA virus infecting 160million individ-
uals worldwide (Gravitz, 2011; Lavanchy, 2011). Hepatitis C is
a slowly progressing disease, which can cause liver fibrosis,
cirrhosis, and hepatocellular carcinoma 15–25 years after
contraction (Seeff, 2002). To date, hepatitis C is the number
one indication for liver transplantation in North America and
Europe. Unfortunately, re-infection of the graft liver by virus
residing in peripheral reservoirs is almost universal and leads
to accelerated disease progression. For post-transplant pa-
tients, interfering with the entry of HCV into the engrafted hepa-
tocytes would be a promising preventive treatment.
HCV penetration is a multistep process requiring the four entry
factors scavenger receptor class B member 1 (SR-BI), CD81,
claudin-1 (CLDN1), and occludin (OCLN) (Evans et al., 2007; Pi-
leri et al., 1998; Ploss et al., 2009; Scarselli et al., 2002). CD81 is a
central player in HCV entry as it directly binds theHCVE2 surface
glycoprotein, renders it fusion competent (Pileri et al., 1998; Ra-
jesh et al., 2012; Sharma et al., 2011), and activates the HCV en-
try cofactor epidermal growth factor receptor (EGFR) (Diao et al.,
2012; Gerold and Rice, 2011; Lupberger et al., 2011). Moreover,
CD81 is thought to laterally translocate with the virions to tight
junctions, where CLDN1 and OCLN reside (Brazzoli et al.,
2008). Finally, CD81 and CLDN1 co-internalize with the virus
into endosomes (Farquhar et al., 2012). How CD81 orchestrates
HCV uptake remained elusive. As a scaffolding protein, CD81
lacks intracellular signaling domains but coordinates protein-
protein interactions in membrane microdomains termed
tetraspanin webs (Charrin et al., 2003; Montpellier et al., 2011).
We hypothesized that the binding of HCV to CD81 triggers pro-
tein interactions, which in turn coordinate HCV uptake.
Here, we determined changes in the protein interaction
network coordinated by CD81 during uptake of HCV particles
using quantitative proteomics (Meissner and Mann, 2014). We
found 26 HCV-dependent CD81 interactions. Consistent with
our hypothesis, a subset of the receptor-interacting proteins
promoted HCV infectivity. In particular, we identified serum
response factor binding protein 1 (SRFBP1) as an HCV host fac-
tor, which forms a complex with CD81 and coordinates host cell
penetration. The method described here is applicable to various
steps in the life cycle of viruses and other microbes. It holds the
promise of revealing critical pathogen-induced changes in host
protein-protein interactions, thus guiding development of anti-
infective strategies.
RESULTS
Quantitative Proteomics Identifies Virus Entry-
Dependent Receptor Interactions
Quantitative proteomics allows the hypothesis-free character-
ization of protein-protein interactions between cellular states.
Here, we use stable isotope labeling by amino acids in cell
culture (SILAC) and quantitative interaction proteomics (Ong
et al., 2002) to studyhost protein interactionswith theHCV recep-
tor CD81 upon HCV exposure. To this end, HCV permissive
human hepatoma cells Huh-7 were labeled with heavy arginine
((15N4
13C6) Arg-10) and lysine ((
15N2
13C6) Lys-8), achieving 95%
incorporation of heavy amino acids into cellular proteins (heavy)
or left unlabeled (light). As HCV induces clathrin-mediated endo-
cytosis 15 min after binding (Coller et al., 2009), we incubated
heavy Huh-7 cells for 15 min with HCV (J6/JFH-1 clone 2; MOI:
10) and light cells with non-infectious cell culture supernatants
(forward label). To exclude isotope-specific effects, we swapped
labels of the two conditions, so that light cells wereHCV exposed
and heavy cells mock treated (reverse label). Next, we affinity en-
riched CD81 and its interacting proteins (Figure S1A), combined
proteins from HCV and uninfected samples, and digested pro-
teins to peptides. Liquid chromatography (LC) coupled to mass
spectrometry (MS) then identified, quantified, and distinguished
peptides derived from HCV and uninfected conditions by their
characteristic mass offset (Figures 1A and S1B).
LC-MS analysis revealed a total of 778 host proteins in CD81
co-immunoprecipitations (co-IPs). This high number is typical
for affinity enrichment MS because it includes proteins, which
non-specifically bind to the IP resin (Table S1) (Keilhauer
et al., 2015). Subsequent data processing eliminates these
background binders as described below. CD81 was detected
in all co-IPs with high intensities independent of the presence
of bound HCV (Figure S1C). To identify HCV-regulated pro-
tein-protein interactions, we next calculated the ratios of heavy
over light protein abundances in cells with or without bound
HCV. Protein quantification was reproducible as demonstrated
by a median correlation of the SILAC ratios of r2 = 0.70 and
0.81 for forward and reverse label samples, respectively.
Here, we focused on proteins, which differed between the
two experimental conditions, thereby excluding backgroundbinders, which are equally abundant in HCV and mock samples.
As hypothesized, we identified 55 protein interactors, which
quantitatively differed between HCV and mock samples. Among
these HCV-dependent transient interactors are proteins
that associate with CD81 (Figure 1B, upper right quadrant) or
dissociate from CD81 upon virus exposure (Figure 1B, lower
left quadrant).
We stratified HCV-dependent interactors of CD81 based on
statistical significance, interaction strength, and biological rele-
vance. In particular, inclusion criteria were a minimum of 2.1-
fold change in CD81 interaction strength upon HCV exposure,
liver expression, and non-nuclear localization. Of note, we addi-
tionally excluded ribosomal proteins in this study, although they
might have a potential role in virus uncoating. A total of 26 pro-
teins fulfilled these inclusion criteria, half of which dissociated
from and the other half associated with CD81 upon virus binding
(labeled data points in Figures 1B and 1C and Table S2; IntAct:
IM-24070). Proteins that were exclusively quantified in the
presence of HCV were assigned an infinite ratio, because the
strength of interaction could not be determined. Known
steady-state interaction partners of CD81 were absent from
this transient interactome. Instead, we identified huntingtin-
interacting-protein-1-related protein (HIP1R), a previously re-
ported HCV entry cofactor and a known component of
clathrin-coated pits (Coller et al., 2009). Taken together, we
confirmed our hypothesis that HCV binding to CD81 alters its
protein interaction network and that some HCV entry cofactors
are transient CD81 interactors.
Next, we investigated whether certain molecular functions and
cellular compartments were enriched in our transient CD81 inter-
actome. Most proteins were membrane associated (49%) or
cytoskeletal components (31%), with one-third being plasma
membrane associated (Figure 1D; Table S3). Molecular function
analysis revealed a strong enrichment for proteins with binding
function (44%), catalytic activity (27%), and structural molecule
activity (15%; Figure 1E; Table S4). Taken together, our gene
ontology (GO) enrichment analysis reflects the fact that the
HCV-CD81 complex laterally translocates along the plasma
membrane (Brazzoli et al., 2008; Coller et al., 2009) with a need
for interaction with plasma membrane and cytoskeletal proteins.
To further reveal interconnected cellular structures and pro-
cesses enriched in the HCV entry-dependent protein pool, we in-
tegrated a DAVID-based clustering analysis in a STRING-based
protein interaction map (Figure 1F). Notably, we found a cluster
of six cellular junction proteins not previously reported in HCV
entry. These proteins, which include adherens junction, desmo-
somal, and cell envelope constituents, are interconnected by re-
ported protein-protein interactions. Furthermore, we found cyto-
skeletal proteins (spectrins; myosin-9) and a clathrin-coated pit
protein (HIP1R), which is in line with the reported clathrin-medi-
ated endocytosis of HCV (Blanchard et al., 2006). Finally, we
found clusters of calcium- and metal-binding proteins as well
as nuclear proteins, with a secondary cytoplasmic localization.
All identified proteins with extracellular or plasma membrane
localization dissociated fromCD81 uponHCV binding (Figure 1F,
blue label), whereas proteins localizing to endosomes or intracel-
lular compartments associated with CD81 (Figure 1F, red label).
This confirms the notion that the HCV-CD81 complex needs toCell Reports 12, 864–878, August 4, 2015 ª2015 The Authors 865
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move out of plasma membrane microdomains to then get endo-
cytosed. In summary, we identified 26 selected transient protein-
receptor interactions during HCV entry including a known HCV
entry cofactor and a cluster of junctional membrane proteins.
Virus-Dependent CD81-Binding Proteins Promote HCV
Infectivity
We hypothesized that a subset of the 26 virus-dependent CD81-
interacting proteins is required for productive virus entry. To test
this, we silenced the 26 respective mRNAs and infected human
hepatoma cells with a Renilla luciferase (RLuc) reporter strain of
HCV (JcR2A; Figure 2A). Eight of the 26 targets showed a signif-
icant reduction in HCV infection of Huh-7.5 cells upon RNAi.
HIP1R, a previously reported HCV cofactor, also decreased
HCV infectivity but did not meet our statistical significance
criteria (Figure 2B; Table S5). CD81-targeting siRNAs served
as positive control and reduced HCV infectivity more than
5-fold. None of the candidate targeting or scrambled siRNAs
were cytotoxic or altered cell proliferation. Cystatin A (CSTA), a
desmosomal regulator, dissociated almost completely from
CD81 upon virus binding (Figures 1B and 1C), and its silencing
led to a significant increase in HCV infectivity (Figure 2B).
Here, we chose to concentrate on the eight transient CD81
interaction partners, which reduced HCV infection when
silenced (Figure 2B). Transcript levels of six of the eight targets
were reduced to 25% or less of scrambled siRNA controls (Fig-
ure S2A). The six putative HCV host factors are SRFBP1, barrier-
to-autointegration factor (BANF1), myosin-9 (MYH9), spectrin
beta chain, non-erythrocytic 1 (SPTBN1), calpactin I light chain
(S100A10), and poly [ADP-ribose] polymerase 1 (PARP1) (Table
S6). Of all tested transient CD81 interactors, SRFBP1 showed
the strongest reduction in HCV infectivity upon knockdown
(z score [SRFBP1]: 6.3; z score [CD81]: 5.8). In summary,
we found that at least six of the 26 tested transient CD81 interac-
tors promote HCV infection with a clear bias for CD81 associ-
ating (five) over dissociating (one) factors (Figures 2C and S2B).
SRFBP1 Is Expressed in the Liver and Required for an
Early Step in HCV Infection
SRFBP1 emerged as prime candidate for in-depth characteriza-
tion as an HCV entry factor because the protein showed the
strongest inhibition of HCV infection when silenced. We first
quantifiedSRFBP1mRNA in primary hepatocytes from resectionFigure 1. High-Resolution Quantitative MS Reveals Transient HCV Ent
(A) Outline of the virus entry interaction proteomics procedure.
(B) CD81 interactome upon HCV exposure. Depicted are the mean log2 SILAC r
forward (y axis) and reverse experiments (x axis). Reverse label ratios are invert
swap. Significant (FDR < 5%) outliers are colored in red (CD81-associating prot
exclusively found in the presence of HCV. n.d., not quantified in either forward o
(C) SILAC log2 ratios for each of the 13 CD81-associating and 13 CD81-dissociat
reverse label ratios.
(D and E) Enrichment of Gene Ontology cellular component (GOCC) and molecu
(F) Functional map of host factors transiently interacting with the HCV receptor CD
interactions (bold lines) of the here identified transient CD81-binding partners are
Yellow lines between genes of different clusters indicate high-confidence (>0.9)
dence (>0.35) STRING interactions are shown. Proteins are placed in their predo
cytoplasm. The box size indicates the degree of CD81 association or dissociation
shown. See also Figure S1 and Tables S1 and S2–S4.specimens of five HCV-negative donors and observed an up
to 6-fold higher SRFBP1 expression level than in Huh-7.5 cells
(Figure 3A). Importantly, SRFBP1 mRNA and protein levels
correlated strongly (Figures S3A and S3B). The observed differ-
ences in SRFBP1 expression led us to examine whether endog-
enous SRFBP1 levels were limiting HCV infection in hepatoma
cells. When overexpressing SRFBP1 in Huh-7.5 cells, we
observed a dose-dependent 2- to 3-fold increase in HCV infec-
tivity (Figure 3B). Conversely, when silencing SRFBP1 in primary
hepatocytes, we observed a 4-fold decrease in HCV infectivity
(Figure S3C). Collectively, this suggests that low SRFBP1
expression could contribute to the limited infectivity in current
HCV cell culture models.
Next, we asked which step in the HCV life cycle requires
SRFBP1. First, we confirmed that infectivity of incoming virus
was impaired in SRFBP1-silenced hepatoma cells. A pool of
three SRFBP1-targeting siRNAs and three individual siRNAs
(nt96, nt394, and nt1038) reduced SRFBP1 protein expression
and resulted in an up to 4-fold reduction in HCV infectivity
(Figure 3C). CD81-silenced cells showed 5-fold decreased
CD81 surface expression and a 10-fold reduction in infectivity
(Figures 3C and S4A). We next excluded off-target effects of
SRFBP1 siRNA nt394 by complementing SRFBP1-silenced
cells with a siRNA-resistant SRFBP1 variant (Figure 3D). Taken
together, silencing of SRFBP1 led to a decrease in HCV sus-
ceptibility, and this phenotype could be rescued by SRFBP1
complementation.
The association of SRFBP1 with the HCV entry factor CD81
suggested a role in HCV entry or an early post-entry event. Our
infectivity readout at 48 hr post-HCV inoculation determined
accumulative effects of virus entry, translation, replication, and
spread (Gerold and Pietschmann, 2014). Thus, we next sought
to exclude that SRFBP1 would affect HCV translation or replica-
tion. When silencing SRFBP1 (nt394) in cells actively replicating
HCV,weobservedno impairmentof replicationandRLuc reporter
translationat 48or 72hr post-RNAi. In stark contrast, silencing the
known replication host factor phosphatidyl inositol 4 kinase 3
alpha (PI4KIIIalpha) reduced replication to background levels
(Figure 3E, upper panel) (Berger et al., 2009; Reiss et al., 2011).
Neither knockdown of SRFBP1 nor of PI4KIIIalpha affected cell
viability or proliferation (Figure 3E, middle panel). To address a
possible role of SRFBP1 in assembly, release, and spread of
HCV, we collected supernatants from HCV-replicating cells atry Factor Interactions
atios of CD81-interacting proteins in HCV versus mock-treated samples from
ed, so that a positive correlation indicates reproducible interaction upon label
eins) and blue (CD81-dissociating proteins). Infinite ratio, interaction partners
r reverse experiment.
ing factors. Shown are means ± SEM of four biological replicates with inverted
lar function (GOMF) annotations.
81 during virus entry. Functional clusters (white boxes) and previously reported
depicted. We assigned individual proteins to the highest scoring DAVID cluster.
STRING interactions. Within a functional annotation cluster, also lower confi-
minant cellular location; SRFBP1 is shown twice as it localizes to nucleus and
upon HCV binding. Associating factors (red) and dissociating factors (blue) are
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Figure 2. A Subset of CD81 Interaction Partners Is Required for HCV Infection
(A) Outline of the RNAi screen on transient CD81 interaction partners relevant for HCV infection.
(B) Functional RNAi follow-up screen on 26 selected transient CD81 interaction partners identifies nine putative host factors. We silenced the indicated transcript
with a pool of three siRNAs in Huh-7.5 FLuc cells, infected 48 hr later withRenilla luciferase reporter HCV (JcR2A), and determined cell viability and HCV infectivity
48 hpi. Shown is the RLuc signal after normalization for cell viability and plate effects. Eight siRNA pools significantly decreased and one increasedHCV infectivity
(p% 0.05; abs [z score]R 2; *). Associating factors (red), dissociating factors (blue), CD81 and scrambled controls (gray) are shown. Box and whisker plot of nine
biological replicates is shown.
(C) The combined SILAC co-IP RNAi strategy reveals a bias for CD81-associating factors to act as HCV host factors. Out of 26 HCV-dependent CD81-binding
partners, six decreased HCV infectivity upon RNAi with a minimum transcript reduction of 75% (shaded color). See also Figure S2 and Tables S5 and S6.48 or 72 hr post-siRNA transfection and infected naive Huh-7.5
cells. SRFBP1 silencing did not alter the released infectivity,
whereas apolipoprotein E (APOE) silencing expectedly reduced
the released infectivity to 40% (Figure 3E, lower panel) (Chang
et al., 2007). Taken together, SRFBP1 silencing rendered cells
less susceptible to HCV without altering replication or spread of
the virus to naive cells.
SRFBP1 Colocalizes with CD81 without Affecting HCV
Receptor Surface Expression
In light of our finding that SRFBP1 plays a role early during HCV
infection, we investigated whether SRFBP1 colocalizes with es-
tablished HCV entry factors in resting cells. Whereas SRFBP1
only weakly colocalized with CLDN1, OCLN, or SR-BI (Pearson’s
coefficient < 0.2), a fraction of the protein colocalized with CD81868 Cell Reports 12, 864–878, August 4, 2015 ª2015 The Authors(Pearson’s coefficient 0.4). In particular, SRFBP1 and CD81 sig-
nals overlapped in perinuclear regions and in the cell periphery,
where we observed a punctate, vesicular staining. We further
observed a weak colocalization with the membrane marker
wheat germ agglutinin (WGA) (Pearson’s coefficient 0.3; Figures
4A and 4B).
Next, we sought to exclude that SRFBP1 acts as a chaperone
for CD81, CLDN1, OCLN, and SR-BI. In adipocytes, SRFBP1 is
required for expression of the insulin-responsive glucose trans-
porter type 4 (GLUT4) and for shuttling of GLUT4 to the plasma
membrane (Lisinski et al., 2006). In contrast, we did not observe
SRFBP1 colocalization with GLUT4 in hepatoma cells (Figures
4A and 4B). In line with these observations, SRFBP1 silencing
in hepatoma cells did not alter surface levels of CD81, CLDN1,
or SR-BI, whereas silencing of CD81 and CLDN1 reduced
Figure 3. The CD81-Binding Partner
SRFBP1 Is Expressed in Human Liver and
Required for HCV Infection
(A) SRFBP1 transcript levels in primary human
hepatocytes are up to 6-fold higher than in Huh-7.5
cells. Absolute transcript numbers of SRFBP1 in
hepatocytes from five donors (D1–D5) and in two
independent passages of human hepatoma cells
(Huh-7.5) were determined in technical triplicates
and displayed as mean + SD.
(B) HCV (JcR2A) infectivity increases in a dose-
dependent manner in Huh-7.5 FLuc cells upon
overexpression of full-length SRFBP1. Cells were
transduced with lentiviruses encoding SRFBP1 or
a blasticidin resistance gene (empty vector), 72 hr
later infected with HCV, and infectivity measured
48 hpi by luciferase assay. Immunoblot analysis
of lysates 72 post-transduction shows dose-
dependent SRFBP1 overexpression (green). Actin
served as loading control (red). The immunoblot is
representative of three biological replicates.
(C) HCV (JcR2A) infectivity is reduced in Huh-7.5
FLuc cells 48 hp silencing of SRFBP1 or CD81.
We used a pool of three siRNAs or individual
siRNAs targeting the indicated ORF position and
measured infectivity at 48 hpi by luciferase assay.
Two scrambled siRNAs (1 and 2) served as
controls. Immunoblot analysis confirms reduced
SRFBP1 protein levels 48 hp RNAi. Mean + SD of
three technical replicates are shown. Infectivity
data and immunoblot are representative of three
biological replicates.
(D) Lentiviral transduction with siRNA-resistant
SRFBP1 rescues HCV infection in SRFBP1-
silenced Huh-7.5 FLuc cells. Cells were trans-
fected with siRNAs (SRFBP1: siRNA 394), 24 hr
later transduced with blasticidin resistance gene
encoding lentivirus (siSRFBP1) or siRNA-resistant
SRFBP1 encoding lentivirus (siSRFBP1 compl.),
and 24 hr later infected with HCV (JcR2A). Infec-
tivity at 48 hpi measured by luciferase assay is
shown.
(E) SRFBP1 is dispensable for HCV replication,
assembly, and release. Huh-7.5 FLuc cells were
transfected with genomic HCV RNA (JcR2A) and
the indicated gene silenced 5 hr later (SRFBP1:
siRNA 394). At 72 and 96 hp transfection (hpt),
supernatants were harvested, cells lysed, and replication efficiency in lysates measured by luciferase assay (upper panel). Viability of HCV-replicating cells upon
RNAi was determined using the cellular FLuc reporter at 72 or 96 hpt (middle panel). Supernatants fromHCV-transfected and SRFBP1-silenced cells were titrated
on naive Huh-7.5 cells to determine virus particle assembly and release rates (bottom panel). Valueswere normalized to a scrambled siRNA control. Unless stated
otherwise, all experiments are displayed as mean + SD of three independent biological replicates each performed in technical triplicates. See also Figure S3.surface expression of the respective protein (Figures 4C and
S4A–S4C). Due to a lack of antibodies targeting the OCLN ecto-
domain, we addressed OCLN expression after knockdown by
immunofluorescence and immunoblot. Total protein levels and
plasma membrane expression of OCLN were similar in Huh-7.5
with or withoutSRFBP1 knockdown (Figure 4D; data not shown).
Similarly, transcript levels of the HCV entry cofactors EGFR and
Niemann-Pick C1-like protein 1 (NPC1L1) (Sainz et al., 2012)
remained unaffected by SRFBP1 silencing (Figure S4D). Taken
together, our data exclude that SRFBP1 acts as chaperone or
transcriptional regulator of one of the previously characterized
HCV entry factors.SRFBP1 Partially Localizes to CD81-Positive
Endosomes and Is Further Recruited to CD81 upon HCV
Glycoprotein Exposure
To better visualize where and when during the HCV entry pro-
cess SRFBP1 comes into play, we performed additional colocal-
ization studies. We detected SRFBP1 in vesicular structures in
the cell periphery, in perinuclear regions, and in heterochromatin
regions of the nucleus. The nuclear localization of SRFBP1 is
consistent with its transcription factor function described in car-
diomyocytes (Zhang et al., 2004). Perinuclear SRFBP1 signals
colocalized with the cytosolic trans-GOLGI marker p230 (Pear-
son’s correlation coefficient 0.4). The punctate, vesicular patternCell Reports 12, 864–878, August 4, 2015 ª2015 The Authors 869
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of SRFBP1 in the cell periphery weakly stained positive for the
endosomal markers EEA and LAMP1, as well as for F andG actin
(Figures 5A and 5B). To achieve more-sensitive visualization of
endosomal compartments, we transfected EGFP-Rab fusion
proteins (Nielsen et al., 1999) into Huh-7.5 cells. We found
overlapping signals for SRFBP1 andCD81 at Rab5-positive early
and late endosomes (Figures 5C and 5D). In favor of a role for
SRFBP1 early during HCV infection, SRFBP1 did not reside
in HCV replication or assembly compartments as shown by
co-staining with the p body marker DDX6, the stress granule
marker ataxin-1, and the lipid droplet dye oil red O (Figures
S5A and S5C).
Next, we asked whether SRFBP1 could interact with intracel-
lular membranes. SRFBP1 has no transmembrane domains, but
we predicted two weak amphipathic helices at the N terminus of
the protein (http://npsa-pbil.ibcp.fr/cgi-bin/npsa_automat.pl?
page=/NPSA/npsa_amphipaseek.html; Sapay et al., 2006). In-
depth analysis revealed that the putative helix at aa108 has a
five-amino-acid hydrophobic side (FLLVI) flanked by lysine resi-
dues (http://heliquest.ipmc.cnrs.fr; Gautier et al., 2008). More-
over, two cysteine residues could serve as palmitoylation sites
(Figure 5E). To confirm that a fraction of SRFBP1 is membrane
associated, we performedmembrane-flotation assays. In accor-
dance with our prediction, a subfraction of endogenous SRFBP1
resided in the upper, membrane-associated gradient fractions
(Figure 5F). As expected, CLDN1 and GAPDH resided in the
upper and lower fractions, respectively. After solubilization of
membranes using Triton X-100, we found endogenous SRFB1
exclusively in the soluble lower fractions and the CLDN1 control
shifted partially to these fractions. Interestingly, a mycDDK-
tagged overexpression construct of SRFBP1 resided in cytosolic
fractions, suggesting that the soluble tag impaired membrane
association of SRFBP1. Our analysis indicates that a fraction
of SRFBP1 can associate with cellular membranes presumably
through a weak amphipathic helix.
To test for relocalization of SRFBP1 during the HCV entry pro-
cess, we exposed Huh-7.5 cells to purified ectodomain of the
HCV E2 glycoprotein (eE2). This resulted in an increased coloc-
alization of SRFBP1 and CD81 (Pearson’s correlation coefficient
0.5), which could be reverted when coadministering an E2 block-
ing antibody (Figures 5G and 5H). Notably, we observed a similar
recruitment of SRFBP1 to CD81-positive compartments in pri-
mary hepatocytes after eE2 exposure (Figures S5B and S5D)
and in hepatoma cells after HCV exposure (Figure S5E). In sum-
mary, our data suggest that SRFBP1 partially resides at intracel-Figure 4. SRFBP1 Colocalizes with CD81 without Affecting Entry Facto
(A) SRFBP1 partially colocalizes with CD81 and the membrane marker WGA but o
with Alexa-conjugated membrane marker WGA (panel 3) for 1 min or left unstain
indicated protein. Nuclei were stained with DAPI. Colocalization across a section
confocal images; insert 2.2-fold magnification; scale bars 10 mm.
(B) Pearson’s correlation coefficient for SRFBP1 and the indicated cellular protein
symbol represents an individual frame; horizontal lines indicate the mean ± SEM
(C) SRFBP1-silenced cells (siRNA 394) express CD81, CLDN1, and SR-BI at the p
cells was analyzed 48 hpt with the indicated siRNAs. Cells were stained with antib
cells per sample. For quantification and additional controls, see Figure S4. Contr
only (histograms 2 and 3).
(D) OCLN expression levels are stable after SRFBP1 silencing (siRNA 394). Im
silencing for 48 hr is shown. Actin served as loading control. Data are representalular membranes in human hepatoma cells and that HCV glyco-
protein exposure promotes colocalization of SRFBP1 and CD81.
SRFBP1, a Pan-genotypic and HCV-Specific Host Entry
Factor
Next, we tested whether SRFBP1 also supports infection with
other enveloped viruses. In Huh-7.5 cells, SRFBP1 silencing
neither reduced infectivity of vesicular stomatitis virus (VSV) or
of human coronavirus 229E (Figures 6A and 6B), hinting that
SRFBP1 is an HCV-specific host factor.
To further elucidate how SRFBP1 aids early HCV infection, we
experimentally addressed HCV translation, replication complex
formation, and membrane fusion. Using a bicistronic HCV
IRES-driven translation reporter, we excluded a role for SRFBP1
in viral genome translation (Figures 6C, 6D, S6A, and S6B). Repli-
cation complex formation of subgenomic and full-length HCV
replicons similarly remained unaltered upon SRFBP1 silencing
(Figures 6E, S6C, and S6D). In linewith this observation, SRFBP1
did not colocalize with the HCV protein NS5A (Pearson’s coeffi-
cient < 0.2; Figures S6E and S6F). We next induced HCV fusion
at the plasma membrane by a low-pH wash and by concomi-
tantly blocking endosomal acidification. In this assay, HCV
enters cells by fusion at the plasma membrane or at the limiting
endosomal membrane before acidification (Figure 6F). As ex-
pected, CD81 silencing led to a 5-fold reduced HCV infectivity,
as CD81 interactions prime the HCV glycoproteins for mem-
brane fusion. Notably, silencing of SRFBP1 reduced HCV infec-
tion by 3-fold, indicating that SRFBP1 functions in cell entry
steps other than the acidification of endosomes. In confirmation
of our assay setup, human coronavirus fusion at the plasma
membrane was independent of pH, whereas VSV required a
low-pH wash. Both coronavirus and VSV infectivity remained
unaffected by SRFBP1 or CD81 silencing in this bypass assay
(Figures S6G and S6H). Taken together, our data show that
SRFBP1 is aiding an early step in HCV infection even when viral
envelope fusion is artificially induced at the plasma membrane.
To pinpoint the requirements of the virus particle toward
SRFBP1 usage, we tested whether lentiviral pseudoparticles
decorated with HCV glycoproteins depend on SRFBP1. Interest-
ingly, lentiviral pseudotypes for HCV genotype 1 (H77) and 2 (J6;
Hsu et al., 2003) transduced SRFBP1-silenced cells efficiently.
CD81 silencing reduced HCV pseudoparticle entry 10-fold,
whereas none of the tested conditions affected control pseudo-
particles carrying VSV glycoproteins (Figure 6G). Thus, SRFBP1
does not affect receptor binding but instead supports anr Surface Expression
nly weakly with CLDN1, OCLN, SR-BI, and GLUT4. Huh-7.5 cells were stained
ed (panels 1, 2, and 4), fixed, permeabilized, and stained for SRFBP1 and the
(yellow line in panel 1) is depicted above the respective image. Representative
or themembranemarkerWGA calculated by intensity correlation analysis. Each
.
lasma membrane. Surface expression of CD81, CLDN1, and SR-BI on Huh-7.5
odies against HCV entry factors followed by flow cytometric analysis of 10,000
ol is directly conjugated isotype antibody (histogram 1) or secondary antibody
munoblot analysis of OCLN (red) and SRFBP1 (green) after siRNA mediated
tive of at least three independent experiments. See also Figure S4.
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infection step not reflected by HCV pseudoparticles. Further-
more, SRFBP1 did not influence lentiviral transduction. Collec-
tively, our results show that SRFBP1 is dispensable for lentiviral
pseudotype, VSV, and coronavirus infection but required to
render cells fully susceptible to HCV.
Lastly, we addressed whether, in addition to cell culture HCV
of genotype 2a, other clinically relevant HCV genotypes require
SRFBP1 for efficient penetration. SRFBP1 interference reduced
infectivity of chimeric viruses displaying the glycoproteins of
either one of the seven HCV genotypes to a similar degree (Fig-
ure 6H). Thus, through quantitative interaction proteomics, we
could identify six putative HCV host factors and, in particular,
SRFBP1 as a pan-genotypic entry factor for HCV.
DISCUSSION
Our results demonstrate that quantitative interaction proteomics
combined with RNAi provides a valuable approach to study
host-pathogen interactions. Quantitative MS provides direct
information on protein-protein interactions and interaction
strength upon perturbation of a cellular system. Here, we
developed a SILAC co-IP strategy to identify host factors, which
transiently interact with the HCV receptor CD81. The data
set allowed generation of a weighted virus entry network and
identification of cellular processes during entry.
Among the identified 26 transient interaction partners of
CD81, four (DSG1, CSTA, DSP, and CDSN) are integral parts
of cellular junctions, in particular desmosomes. These proteins
dissociated from CD81 during virus entry, suggesting that the
virus receptor complex leaves desmosomal membrane com-
partments during uptake. The second enriched cluster of
Ca2+-binding proteins (CALML5, S100A7, and S100A10) could
contribute to the reported Ca2+-dependent ER stress and
deregulation of Ca2+ homeostasis induced by HCV (Benali-Furet
et al., 2005; Piccoli et al., 2009). Here, we focused on CD81
interaction partners, which support HCV infection, and found
that these comprise at least 23% of the 26 interactors. The pu-
tative HCV host factors are SRFBP1, S100A10, BANF1, PARP1,Figure 5. A Pool of SRFBP1 Localizes to CD81 on Endosomes and Is R
(A) SRFBP1 localizes to the trans-GOLGI, endosomes, and actin. Huh-7.5 cells
markers EEA1, LBPA, and LAMP1 as described in Figure 4A. F and G actin were
(B) Pearson’s correlation coefficient for SRFBP1 and indicated cellular proteins ca
frame; horizontal lines indicate the mean ± SEM.
(C) SRFBP1 localizes to CD81 on endosomes. Huh-7.5 cells were transfected
SRFBP1 and CD81. Colocalization of SRFBP1, CD81, and Rab proteins across
colocalization.
(D) SRFBP1 and CD81 colocalize at early endosomes. Quantification of SRFBP1,
median, minimum, and maximum values from six independent frames.
(E) Bioinformatics prediction of two weak amphipathic helices for SRFBP1 (black
five amino acids (FLLVI). The hydrophobic face is highlighted in light gray in the pr
and aa 300), which could serve as palmitoylation sites, are indicated by arrowhe
(F) Membrane flotation assay suggests membrane association of SRFBP1. Huh-
hypotonic buffer, and analyzed byNycodenz gradient ultracentrifugation followed
lysates served as solubilization control. L, precleared lysate; M, marker; P, pellet
(G) Exposure to soluble HCV glycoprotein (eE2) increases SRFBP1-CD81 coloc
blocking antibody (a-E2), or with PBS (mock) for 15 min; fixed; and stained for SR
(H) Pearson’s correlation coefficient for SRFBP1 and CD81 calculated by intensi
lines indicate the mean ± SEM; p value is indicated.
Representative images; inserts show magnification; scale bars 10 mm (A and C)MYH9, and SPTBN1 (Table S6). The latter two guide cytoskel-
eton movement at the plasma membrane, which is in line
with the reported membrane ‘‘surfing’’ of HCV (Brazzoli et al.,
2008). S100A10 is a component of the annexin 2 heterotetramer
and regulates membrane organization and endocytosis. We
conclude that quantitative proteomics can identify functional
virus-host cell interactions.
Several HCV host factors described in this study play a role in
the life cycle of other enveloped viruses. MYH9 (also known as
myosin IIA) regulates Kaposi’s sarcoma-associated herpesvirus
macropinocytosis (Valiya Veettil et al., 2010). S100A10 is phos-
phorylated by the HCV host factor EGFR (Lupberger et al.,
2011) and promotes uptake of papillomaviruses upon EGFR-
driven phosphorylation (Dziduszko and Ozbun, 2013; Woodham
et al., 2012). The protein is also thought to be a cofactor for entry
of HIV-1, cytomegalovirus, and respiratory syncytial virus (Ma
et al., 2004; Malhotra et al., 2003; Raynor et al., 1999). BANF1
is involved in nuclear DNA repair and HIV-1 genome integration
(Chen and Engelman, 1998) and senses vaccinia virus genomes
in the cytoplasm (Ibrahim et al., 2011). PARP1 has poly(ADP-
ribosyl)ation activity and is sequestered to the cytoplasm during
HIV-1 and Sindbis virus infection (Muthumani et al., 2006; Park
and Griffin, 2009). Hence, we identified six putative HCV host
factors, which are linked to known HCV entry machineries,
e.g., clathrin-mediated endocytosis and EGFR signaling, or
have a reported role in infection or sensing of other enveloped
viruses.
SRFBP1 emerged as prime candidate for follow up and
proof of principle analysis as the protein had the strongest
RNAi phenotype in our screen. The protein promotes plasma
membrane expression of GLUT4 in adipocytes (Lisinski et al.,
2006), associates with actin, and has transcription factor activity
in cardiomyocytes (Zhang et al., 2004, 2014). In this study, we
identify SRFBP1 as transient binding partner of the HCV recep-
tor CD81 in human hepatoma cells. Our results demonstrate
that SRFBP1 is required for productive uptake of HCV without
affecting expression or membrane localization of known
HCV entry factors. We further show that primary hepatocytesecruited to CD81 upon HCV Glycoprotein Exposure
were stained for SRFBP1; the trans-GOLGI marker p230; and the endosomal
stained with Alexa-conjugated phalloidin and DNase I, respectively.
lculated by intensity correlation analysis. Each symbol represents an individual
with expression plasmids for EGFP-Rab4, -Rab5, and -Rab7 and stained for
a section (yellow line) is depicted in the upper panels. Arrowheads indicate
CD81, and Rab triple-positive puncta is shown. Box and whisker plot showing
bars) with the second helix (aas 108–128) showing a small hydrophobic face of
imary sequence and in yellow in the helix model. Two cysteine residues (aa 254
ads.
7.5 cells were transduced with mycDDK-tagged SRFBP1, 48 hr later lysed in
by immunoblot analysis against SRFBP1, GAPDH, andCLDN1. TX-100-treated
after lysate preclearing. One out of three independent experiments is shown.
alization in Huh-7.5 cells. Cells were incubated with eE2, with eE2 and an E2
FBP1 and CD81 as described in Figure 4A. Arrowheads indicate colocalization.
ty correlation analysis. Each symbol represents an individual frame; horizontal
and 20 mm (G). See also Figure S5.
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Figure 6. SRFBP1 Is a Pan-genotypic and HCV-Specific Host Entry Factor
(A) SRFBP1 is dispensable for VSV infection. SRFBP1-silenced Huh-7.5 cells were infected with VSV*MQ (MOI 0.1) and analyzed for GFP expression by flow
cytometry 20 hpi. Histogram is representative of biological triplicates (left panel). Quantification of VSV*MQ infectivity 20 hpi in SRFBP1-silenced cells
is determined as percentage of GFP-positive cells (middle panel) or by normalization of the mean fluorescence intensity (MFI) of VSV-infected SRFBP1- or
CD81-silenced cells to MFI of scrambled siRNA-transfected cells (right panel).
(legend continued on next page)
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express up to 6-fold higher transcript levels of SRFBP1 than
hepatoma cells, in which SRFBP1 expression seems to limit
HCV infectivity. Thus, SRFBP1 might play a critical role in
HCV infection in patients.
Collectively, our data suggest that SRFBP1 is a bona fide entry
factor for HCV (Figure 7). During the HCV entry pathway,
SRFBP1 supports a step independent of receptor binding, cla-
thrin-mediated endocytosis, and endosomal acidification. The
latter three steps are reliably mimicked by lentiviral HCV pseudo-
types, which enter cells independent of SRFBP1. The observed
discrepancy between cell culture HCV and HCV pseudoparticles
confirms other studies suggesting that HCV pseudoparticles
cannot fully mimic the entry pathway of HCV (Sainz et al.,
2012). This can be attributed either to the lower avidity of HCV
pseudoparticles, which display a lower density of glycoproteins,
to the lack of serum lipoprotein association of HCV pseudopar-
ticles, or to the different nucleocapsid.
Here, we propose two possible modes of action of SRFBP1
during HCV entry. First, SRFBP1 could be involved in actin retro-
grade transport of HCV particles as observed by Coller et al.
(2009). Such actin cortex remodeling is not induced by HCV
pseudoparticles (Harris et al., 2013). Second, SRFBP1 might
assist HCV uncoating or nucleocapsid transport, both of which
are not reflected by the pseudoparticle system. Generally,
SRFBP1 could be the missing link between HCV receptor bind-
ing and actin-dependent movement during HCV invasion.
Indeed, we observed an interaction of SRFBP1 with G actin.
Moreover, EGFR, Arp2/3, Rho GEFs, and Rho GTPases are
reported upstream activators of the SRFBP1 protein family and
at the same time support HCV entry (Brazzoli et al., 2008; Lup-
berger et al., 2011; Zona et al., 2013). Future studies including
high-resolution imaging will be necessary to experimentally vali-
date either model.
The endogenous function of cytoplasmic SRFBP1 is currently
elusive. In rat cardiomyocytes, SRFBP1 localizes to actin fibers
close to their attachment site to the cell cortex and SRFBP1
overexpression leads to actin depolymerization (Zhang et al.,
2014). This hints that SRFBP1 belongs to the class of myocar-(B) SRFBP1 is dispensable for coronavirus infection. SRFBP1-silenced cells w
measured 24 hpi. Infectivity relative to a scrambled siRNA control is shown.
(C) Immunoblot analysis of SRFBP1 and CD81 48 hp siRNA transfection. Huh-7
expression construct as in (A)–(H), 48 hr later lysed, and analyzed by immunoblo
(D) Bicistronic translational reporter assay with HCV IRES-driven RLuc and ca
overexpression was performed as in (C), and 48 hr later, cells were transfected w
activity in lysates was monitored.
(E) Early replication reporter assay using a subgenomic HCV genome expressing F
later, JFH-SGR-FLuc RNA was transfected into cells; cells lysed after 8 hr; and
(DGDD) was used to assess translation of HCV genomes independent of de nov
(F) SRFBP1 is required in a plasmamembrane fusion assay of HCV infection. Huh-
to block vacuolar type H+-ATPases, incubated with HCV (JcR2A) for 2 hr at 4C in t
7 buffer for 5 min. After incubation with concanamycin A for 4 hr, medium was cha
See also Figures S6E and S6F for additional controls.
(G) Lentiviral pseudotypes infect Huh-7.5 cells independently of SRFBP1. Cells in
encoding FLuc and displaying glycoproteins from HCV genotype 1 (H77), HCV g
activity measured. Infectivity was calculated by subtraction of background read
(H) Silencing of SRFBP1 reduces infectivity of chimeric HCV viruses with glycopr
mediated silencing followed by infection with intergenotypic HCV chimeras (MO
mined by RLuc activity measurement. Cells treated with CD81 targeting or scram
experiments. Data from three to five biological replicates are displayed as meandin-related transcription factor (MRTF) cofactors (Olson and
Nordheim, 2010), which regulate actin polymerization by cycling
between a G-actin-bound cytoplasmic state and a nuclear state.
Concordantly, we found SRFBP1 in the nucleus and at cyto-
plasmic G actin in human hepatoma cells. Like other MRTF
cofactors, SRFBP1 could regulate actin dynamics downstream
of plasma membrane receptor signaling. In line with this, CD81
engagement by antibodies was recently reported to promote
actin-dependent hepatoma spread (Brimacombe et al., 2014).
Thus, HCV might exploit endogenous mechanisms of physical
force generation to traffic during its entry.
Taken together, we established a combination of high-resolu-
tion MS, computational proteomics, and RNAi to elucidate
receptor complex rearrangements during HCV entry. We believe
that quantitative interaction proteomics is an attractive strategy
to identify host factors of infectious agents. A particular strength
lies in the unbiased identification of yet uncharacterized proteins
as we demonstrate for SRFBP1, a protein with previously
unknown function in hepatocytes. Moreover, interaction prote-
omics allows the identification of host factors, which are ubiqui-
tously expressed, and are thus not accessible by genetic
complementation screens. Similarly, host factors with essential
endogenous function are poorly suited for stable knockdown
or knockout screens and can readily be found by quantitative
proteomics. Thus, the minimal system perturbation during the
above-described workflow is a clear benefit over classical
genetic screening methods. On the other hand, functional infor-
mation on the identified host factors is limited to the interaction
with a given virus receptor. A functional follow-up screen, as
we describe here, is therefore critical to evaluate the protein
interaction data. Consequently, interaction proteomics is a com-
plementary method in the thus far genomics-oriented toolbox for
systems virology (Law et al., 2013). As for other systems biology
methods, interaction proteomics is not error free. Although
detection limits for MS fingerprinting have increased tremen-
dously in the past years (Cox and Mann, 2012), false negatives
might arise depending on the affinity enrichment method used.
False positive interactions could obviously arise after cell lysisere infected with HCoV229E-luc (MOI 0.1) and RLuc activity in cell lysates
.5 cells were transfected with siRNA or transduced with the indicated pWPI
t. Actin served as loading control. *, residual SRFBP1 signal.
p-dependent FLuc (see also Figures S6A and S6B). SRFBP1 silencing and
ith translational reporter RNA. Eight hours after reporter transfection, luciferase
Luc. SRFBP1 silencing and overexpression was performed as in (C), and 48 hr
luciferase activity monitored. A polymerase mutant JFH-SGR-FLuc replicon
o replication. See also Figures S6C and S6D for additional controls.
7.5 cells silenced forSRFBP1were pretreatedwith concanamycin A (5 nM; 1 hr)
he presence of concanamycin A, shifted to 37C, andwashedwith a pH 5 or pH
nged and endosomal acidification independent infectivity measured at 48 hpi.
which SRFBP1 had been silenced (48 hr) were infected with HIV-1 pseudotypes
enotype 2 (J6), VSV, or no glycoprotein. At 72 hpi, cells were lysed and FLuc
for glycoprotein-free particles and relative to VSVG particles.
oteins from all seven genotypes. Huh-7.5 FLuc cells were subjected to siRNA-
I 0.1) expressing RLuc. Forty-eight hours post-infection, infectivity was deter-
bled siRNAs served as controls. SRFBP1-targeting siRNA 394 was used in all
+ SD. See also Figure S6.
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Figure 7. HCV Life Cycle and Possible Role
for SRFBP1 during HCV Entry
Our data point toward a role for SRFBP1 in the last
step of entry; i.e., nucleocapsid uncoating.and disruption of cellular compartments, and thus, careful
follow-up analysis is critical for the here-describedmethodology.
Clearly, receptor interaction proteomics will not only allow the
follow-up search for entry factors but can also reveal host factors
involved in innate immune recognition or cellular perturbations
triggered by the virus like, e.g., apoptosis (Figure S7). Given
that co-IP proteomics reveals interconnectivity of pathogen re-
ceptors and host cofactors, we envision that the technique can
spur the development of peptidomimetics or small molecules
for therapeutic intervention of pathogen invasion (de Chassey
et al., 2012).
EXPERIMENTAL PROCEDURES
SILAC Labeling and HCV Inoculation
Huh-7 cells were passaged eight times in light or heavy label media, i.e.,
Arg- and Lys-free DMEM (PAA Laboratories) supplemented with 2 mM
L-glutamine, 1 mM pyruvate, 10% dialyzed FBS, 0.375% sodium bicarbon-
ate, 48 mg/ml Arg (Arg-0, Arg-6, and Arg-10, respectively), and 73 mg/ml Lys
(Lys-0 and Lys-8, respectively; Cambridge Isotope Labs). Confluent P150
cultures were incubated with J6/JFH clone 2 (MOI 10 after 1:5 dilution in
serum-free label media) for 15 min at 37C or treated in a similar manner
with virus-free conditioned cell culture media processed in the same way876 Cell Reports 12, 864–878, August 4, 2015 ª2015 The Authorsas the HCV preparation (mock electroporation).
One-step immunoprecipitations of membrane
proteins were performed as detailed in the Sup-
plemental Experimental Procedures. Experiments
were conducted in four replicates (two heavy-




Mass spectra were acquired and analyzed as
described in the Supplemental Experimental Pro-
cedures. For each HCV and mock-treated SILAC
pair with a given label combination, normalized
ratios were calculated from the individual heavy
and light peptide intensities as described in Cox
and Mann (2008).
Transient protein interactions (i.e., regulated
CD81 binding during HCV entry) were defined by
differing significantly from the main distribution of
steady-state interactors using significance B with
a false discovery rate of 5% as described in Cox
and Mann (2008). By this analysis, 55 proteins
from a total of 778 proteins were identified, which
grouped into 29 associating and 26 dissociating
proteins (Table S1). Proteins were required to be
significantly regulated in at least one experiment to
be included for furtheranalysis. Toquantifyproteins,
which were only detected in one experimental
condition (HCV or mock), we analyzed the total ion
intensities for heavy and light peptides separately.
We detected five proteins exclusively in HCV
samples, fourofwhichwere liver expressed.Nopro-
teins were exclusively detected in mock samples.Proteins significantly regulated upon HCV incubation were ranked by their
fold change and only those with >2.1-fold change considered for further
analysis. Forty-seven interaction partners of CD81 fulfilled this criterion. For
functional follow up of CD81-binding proteins, we additionally filtered for
expression in human liver and for subcellular localization. Proteins with lacking
liver expression or strict ribosomal and nuclear localization were excluded
from downstream analysis, resulting in 26 selected CD81-binding partners
to be tested for their role in HCV infection.
The protein interactions from this publication have been submitted to
the IMEx (http://www.imexconsortium.org) consortium through IntAct and
assigned the identifier IM-24070 (Orchard et al., 2014).RNAi Screen for HCV Host Factors and Bioinformatic Analysis
Huh-7.5 cells stably expressing Firefly luciferase (Huh-7.5 FLuc) were
transfected with pools of three siRNAs against the 26 selected transient
CD81 interaction partners (Ambion Silencer Select) and infected with the
Renilla luciferase reporter virus JcR2A (MOI 0.1) as detailed in the Supple-
mental Experimental Procedures. The screen was performed nine times on
Huh-7.5 FLuc cells of three independent passages. Normalization and statis-
tical analysis was performed on a set of 34 targets total in R using the
Bioconductor package RNAither (Rieber et al., 2009).
Cell lines, viruses, used reagents, and detailed methods are described in the
Supplemental Experimental Procedures. Human samples were handled under
oversight of the ethics committee of the Hannover Medical School.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
seven figures, and six tables and can be found with this article online at
http://dx.doi.org/10.1016/j.celrep.2015.06.063.
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